Compare MCD & MRK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MCD | MRK |
|---|---|---|
| Founded | 1940 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Restaurants | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 217.9B | 260.2B |
| IPO Year | N/A | N/A |
| Metric | MCD | MRK |
|---|---|---|
| Price | $304.22 | $102.33 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 25 | 14 |
| Target Price | ★ $326.35 | $108.21 |
| AVG Volume (30 Days) | 3.3M | ★ 15.2M |
| Earning Date | 11-05-2025 | 10-30-2025 |
| Dividend Yield | 2.45% | ★ 3.34% |
| EPS Growth | 2.90 | ★ 58.08 |
| EPS | ★ 11.72 | 7.56 |
| Revenue | $26,264,000,000.00 | ★ $64,235,000,000.00 |
| Revenue This Year | $4.17 | $1.82 |
| Revenue Next Year | $5.66 | $5.10 |
| P/E Ratio | $25.90 | ★ $13.48 |
| Revenue Growth | 1.25 | ★ 1.68 |
| 52 Week Low | $276.53 | $73.31 |
| 52 Week High | $326.32 | $105.84 |
| Indicator | MCD | MRK |
|---|---|---|
| Relative Strength Index (RSI) | 48.45 | 70.14 |
| Support Level | $304.03 | $93.90 |
| Resistance Level | $313.30 | $105.84 |
| Average True Range (ATR) | 4.43 | 3.22 |
| MACD | 0.41 | 1.08 |
| Stochastic Oscillator | 28.62 | 80.65 |
McDonald's is the largest restaurant owner-operator in the world, with 2024 system sales of $131 billion across more than 43,000 stores and 115 markets. McDonald's pioneered the franchise model, building its footprint through partnerships with independent restaurant franchisees and master franchise partners around the globe. The firm earns roughly 60% of its revenue from franchise royalty fees and lease payments, with most of the remainder coming from company-operated stores across its three core segments: the United States, internationally operated markets, and international developmental/licensed markets.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform, led by Keytruda, is a major contributor to overall sales. The company also has a substantial vaccine business aimed at preventing pediatric diseases, as well as Gardasil for human papillomavirus. Additionally, Merck sells animal health-related drugs. From a geographical perspective, 47% of the company's sales are generated from US human health (pharmaceuticals and vaccines).